How an immune molecule makes cancer cells starve
1/31/2014
The name of the Interferon-beta (IFN-β) molecule and the English word "interfere" go back to the same Latin roots. And interfering is exactly what this messenger molecule, whose formation is increased in infections and cancer diseases, does. Consequently, it is often administered therapeutically.
Lightwaves used by neuroscientists to improve brain tumor surgery
1/31/2014
First-of-its-kind research by the Innovation Institute at Henry Ford Hospital shows promise for developing a method of clearly identifying cancerous tissue during surgery on one of the most common and deadliest types of brain tumor.
A new study reports that in the absence of biopsy-proven invasive cancer, a second colonoscopy done at an expert center may be appropriate to reevaluate patients referred for surgical resection. In the study, 71 percent of the lesions referred for surgery were noncancerous polyps (growths in the colon) and were treatable endoscopically.
A new study reports that in the absence of biopsy-proven invasive cancer, a second colonoscopy done at an expert center may be appropriate to reevaluate patients referred for surgical resection. In the study, 71 percent of the lesions referred for surgery were noncancerous polyps (growths in the colon) and were treatable endoscopically.
New study finds link between slow reaction time and early death
1/30/2014
A new study, published in the journal PLOS ONE, has found that adults who have slow reaction times have a higher risk of an early death.Reaction time was studied because it reflects how well the central nervous system is working. It also reflects basic mental skills, such as how quickly a person is able to process information.
Final results from the Phase 3 PREVAIL trial of enzalutamide
1/30/2014
Medivation Inc. and Astellas Pharma Inc. have announced final results on the primary and secondary efficacy endpoints from the Phase 3 PREVAIL trial of enzalutamide in patients with chemotherapy-naïve metastatic prostate cancer who have failed androgen deprivation therapy and have few or no symptoms.
Provectus announces PV-10's assessment for drug-drug interaction potential
1/30/2014
Provectus Biopharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, and XenoTech, a preclinical CRO and pioneer in collaborative research surrounding in vitro drug metabolism and pharmacokinetics (DMPK) services, has announced that an article describing a study to determine the potential of rose bengal disodium to cause drug-drug interactions has been...
Classification system for bladder cancer prognosis
1/30/2014
Researchers at Lund University have developed a classification system to determine the prognosis for bladder cancer. It is hoped that this will prove useful for future bladder cancer research and drug development.
Mouse model demonstrates role for metabolic enzyme in acute myeloid leukemia
1/30/2014
In recent years, mutations in two metabolic enzymes, isocitrate dehydrogenase-1 and 2 (IDH1 and IDH2), have been identified in approximately 20 percent of all acute myeloid leukemias (AML). As a result, mutant IDH proteins have been proposed as attractive drug targets for this common form of adult leukemia.
In certain breast cancers, melatonin shows potential to slow tumor growth
1/30/2014
An early stage study shows melatonin - a hormone that regulates the body's sleep and awake cycles - may have the potential to help slow the growth of certain breast cancer tumors, according to researchers from Henry Ford Hospital in Detroit and Foundation for Research Support of the State of São Paulo.